Amneal Pharmaceuticals (AMRX) to Release Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing its earnings results before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. The firm had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $6.05 on Wednesday. The company’s 50-day moving average price is $5.72 and its 200-day moving average price is $5.24. Amneal Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $6.46. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31. The company has a market cap of $1.86 billion, a PE ratio of -19.52 and a beta of 1.33.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. The Goldman Sachs Group lifted their price target on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research note on Monday, March 4th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.